Emulsion formulations of an NK-1 receptor antagonist and uses thereof
US11173118B2 · kind B2 · utility
6Cited by
7References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2020 |
| Grant date | Nov 16, 2021 |
| Priority date | — |
| Expiry date | Mar 16, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG06N7/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.